TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE EUROPE KIDNEY CANCER DIAGNOSTICS MARKET 84
1.4 CURRENCY AND PRICING 86
1.5 LIMITATIONS 87
1.6 MARKETS COVERED 87
2 MARKET SEGMENTATION 91
2.1 MARKETS COVERED 91
2.2 GEOGRAPHICAL SCOPE 92
2.3 YEARS CONSIDERED FOR THE STUDY 93
2.4 DBMR TRIPOD DATA VALIDATION MODEL 94
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
2.6 MULTIVARIATE MODELLING 98
2.7 MARKET APPLICATION COVERAGE GRID 99
2.8 TEST TYPE LIFELINE CURVE 100
2.9 DBMR MARKET POSITION GRID 101
2.10 VENDOR SHARE ANALYSIS 102
2.11 SECONDARY SOURCES 103
2.12 ASSUMPTIONS 103
3 EXECUTIVE SUMMARY 104
4 PREMIUM INSIGHTS 107
4.1 PESTEL ANALYSIS 108
4.2 PORTER'S 5 FORCES 109
4.3 EPIDEMIOLOGY 110
4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES 111
4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES 111
5 INDUSTRY INSIGHTS 112
6 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS 114
7 MARKET OVERVIEW 117
7.1 DRIVERS 119
7.1.1 GROWING PREVALENCE OF KIDNEY CANCER 119
7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER 121
7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 122
7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER 122
7.2 RESTRAINTS 123
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS 123
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 124
7.3 OPPORTUNITIES 124
7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 124
7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS 125
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 125
7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 126
7.4 CHALLENGES 126
7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 126
7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS 127
8 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE 128
8.1 OVERVIEW 129
8.2 IMAGING 133
8.2.1 COMPUTED TOMOGRAPHY 134
8.2.2 ULTRASOUND 134
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 134
8.2.4 ANGIOGRAPHY 134
8.2.5 X-RAY 134
8.2.6 OTHERS 134
8.3 BLOOD TEST 134
8.4 BIOPSY 135
8.4.1 FINE NEEDLE ASPIRATION 136
8.4.2 NEEDLE CORE BIOPSY 136
8.5 BIOMARKER TEST 136
8.5.1 AQUAPORIN 1 (AQP1) 138
8.5.2 PERILIPIN (PLIN2) 138
8.5.3 N-METHYLTRANSFERASE (NMNT) 138
8.5.4 L-PLASTIN (LCP-1) 138
8.5.5 NM23A 138
8.6 GENETIC TEST 138
8.7 OTHERS 139
9 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 141
9.1 OVERVIEW 142
9.2 STAGE I 145
9.3 STAGE II 145
9.4 STAGE III 146
9.5 STAGE IV 147
10 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 148
10.1 OVERVIEW 149
10.2 RENAL CELL CARCINOMA 153
10.2.1 IMAGING 154
10.2.2 BLOOD TEST 154
10.2.3 BIOPSY 154
10.2.4 BIOMARKER TEST 154
10.2.5 GENETIC TEST 154
10.2.6 OTHERS 154
10.3 CLEAR CELL RENAL CELL CARCINOMA 154
10.3.1 IMAGING 156
10.3.2 BLOOD TEST 156
10.3.3 BIOPSY 156
10.3.4 BIOMARKER TEST 156
10.3.5 GENETIC TEST 156
10.3.6 OTHERS 156
10.4 NON CLEAR CELL RENAL CELL CARCINOMA 156
10.4.1 PAPILLARY RENAL CELL CARCINOMA 157
10.4.1.1 IMAGING 158
10.4.1.2 BLOOD TEST 158
10.4.1.3 BIOPSY 158
10.4.1.4 BIOMARKER TEST 158
10.4.1.5 GENETIC TEST 158
10.4.1.6 OTHERS 158
10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 158
10.4.2.1 IMAGING 159
10.4.2.2 BLOOD TEST 159
10.4.2.3 BIOPSY 159
10.4.2.4 BIOMARKER TEST 159
10.4.2.5 GENETIC TEST 159
10.4.2.6 OTHERS 159
11 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 160
11.1 OVERVIEW 161
11.2 INSTRUMENT BASED PRODUCTS 165
11.2.1 IMAGING 166
11.2.2 BIOPSY 166
11.3 PLATFORM BASED PRODUCTS 166
11.3.1 NEXT GENERATION SEQUENCING 168
11.3.2 MICROARRAYS 168
11.3.3 PCR 169
11.3.4 OTHERS 169
11.4 KITS AND REAGENTS 169
11.4.1 RENAL CANCER PANELS 171
11.4.2 RENAL CANCER ANTIBODIES 171
11.5 OTHER CONSUMABLES 171
12 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 172
12.1 OVERVIEW 173
12.2 FLUORESCENT IN SITU HYBRIDIZATION 176
12.3 NEXT GENERATION SEQUENCING 176
12.4 FLUORIMMUNOASSAY 177
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 178
12.6 IMMUNOHISTOCHEMICAL 179
12.7 OTHERS 179
13 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 181
13.1 OVERVIEW 182
13.2 SCREENING 185
13.2.1 INSTRUMENT BASED PRODUCTS 186
13.2.2 PLATFORM BASED PRODUCTS 186
13.2.3 KITS AND REAGENTS 186
13.2.4 OTHER CONSUMABLES 186
13.3 DIAGNOSTIC AND PREDICTIVE 186
13.3.1 INSTRUMENT BASED PRODUCTS 187
13.3.2 PLATFORM BASED PRODUCTS 187
13.3.3 KITS AND REAGENTS 187
13.3.4 OTHER CONSUMABLES 187
13.4 PROGNOSTIC 188
13.4.1 INSTRUMENT BASED PRODUCTS 189
13.4.2 PLATFORM BASED PRODUCTS 189
13.4.3 KITS AND REAGENTS 189
13.4.4 OTHER CONSUMABLES 189
13.5 RESEARCH 189
13.5.1 INSTRUMENT BASED PRODUCTS 190
13.5.2 PLATFORM BASED PRODUCTS 190
13.5.3 KITS AND REAGENTS 190
13.5.4 OTHER CONSUMABLES 191
14 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER 192
14.1 OVERVIEW 193
14.2 HOSPITALS 196
14.3 DIAGNOSTIC CENTERS 196
14.4 CANCER RESEARCH CENTERS 197
14.5 ACADEMIC INSTITUTES 198
14.6 AMBULATORY SURGICAL CENTERS 198
14.7 OTHERS 199
15 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 200
15.1 OVERVIEW 201
15.2 DIRECT TENDER 204
15.3 RETAIL SALES 204
15.4 OTHERS 205
16 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION 206
16.1 EUROPE 207
16.1.1 GERMANY 223
16.1.2 FRANCE 232
16.1.3 UNITED KINGDOM 241
16.1.4 ITALY 250
16.1.5 SPAIN 259
16.1.6 RUSSIA 268
16.1.7 NETHERLANDS 277
16.1.8 POLAND 286
16.1.9 SWITZERLAND 295
16.1.10 BELGIUM 304
16.1.11 SWEDEN 313
16.1.12 NORWAY 322
16.1.13 DENMARK 331
16.1.14 FINLAND 340
16.1.15 TURKEY 349
16.1.16 REST OF EUROPE 358
17 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 359
17.1 COMPANY SHARE ANALYSIS: EUROPE 359
18 SWOT ANALYSIS 360
19 COMPANY PROFILE 361
19.1 CANON MEDICAL SYSTEMS CORPORATION 361
19.1.1 COMPANY SNAPSHOT 361
19.1.2 REVENUE ANALYSIS 361
19.1.3 COMPANY PROFILE 362
19.1.4 PRODUCT PORTFOLIO 362
19.1.5 RECENT DEVELOPMENT 362
19.2 KONINKLIJKE PHILIPS N.V. 363
19.2.1 COMPANY SNAPSHOT 363
19.2.2 REVENUE ANALYSIS 363
19.2.3 COMPANY PROFILE 364
19.2.4 PRODUCT PORTFOLIO 364
19.2.5 RECENT DEVELOPMENTS 365
19.3 GENERAL ELECTRIC COMPANY 366
19.3.1 COMPANY SNAPSHOT 366
19.3.2 REVENUE ANALYSIS 366
19.3.3 COMPANY PROFILE 367
19.3.4 PRODUCT PORTFOLIO 367
19.3.5 RECENT DEVELOPMENTS 368
19.4 SIEMENS HEALTHCARE GMBH 369
19.4.1 COMPANY SNAPSHOT 369
19.4.2 REVENUE ANALYSIS 369
19.4.3 COMPANY PROFILE 370
19.4.4 PRODUCT PORTFOLIO 370
19.4.5 RECENT DEVELOPMENT 371
19.5 GRAIL 372
19.5.1 COMPANY SNAPSHOT 372
19.5.2 PRODUCT PORTFOLIO 372
19.5.3 RECENT DEVELOPMENTS 372
19.6 AMBRY GENETICS 374
19.6.1 COMPANY SNAPSHOT 374
19.6.2 PRODUCT PORTFOLIO 374
19.6.3 RECENT DEVELOPMENT 374
19.7 BIOVENDOR R&D 375
19.7.1 COMPANY SNAPSHOT 375
19.7.2 PRODUCT PORTFOLIO 375
19.7.3 RECENT DEVELOPMENT 375
19.8 BLUEPRINT GENETICS OY. 376
19.8.1 COMPANY SNAPSHOT 376
19.8.2 PRODUCT PORTFOLIO 376
19.8.3 RECENT DEVELOPMENT 376
19.9 CD GENOMICS 377
19.9.1 COMPANY SNAPSHOT 377
19.9.2 PRODUCT PORTFOLIO 377
19.9.3 RECENT DEVELOPMENT 377
19.10 CENTOGENE N.V. 378
19.10.1 COMPANY SNAPSHOT 378
19.10.2 REVENUE ANALYSIS 378
19.10.3 PRODUCT PORTFOLIO 379
19.10.4 RECENT DEVELOPMENT 379

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.